Tandem Diabetes Care (TNDM) Income from Continuing Operations (2013 - 2026)
Tandem Diabetes Care (TNDM) posted Income from Continuing Operations of 20400000.0 for Q1 2026, down 3656.91% on a QoQ basis from 543000.0 in Q4 2025, and up 84.38% year-over-year from 11064119.6 in Q1 2025.
Tandem Diabetes Care (TNDM) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 20400000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 84.38% year-over-year to 20400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94530000.0 (up 48.59% YoY) and the FY2025 annual result came in at 204710000.0, down 113.18% from the prior year.
- Income from Continuing Operations was 20400000.0 for Q1 2026 at Tandem Diabetes Care, down from 543000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 755000.0 in Q4 2024 and bottomed at 130600000.0 in Q1 2025.
- A 5-year average of 37549117.65 and a median of 29967000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 951.88% — and 2024, when it soared 102.52%.
- Tandem Diabetes Care's Income from Continuing Operations stood at 15891000.0 in 2022, then slumped by 88.58% to 29967000.0 in 2023, then jumped by 102.52% to 755000.0 in 2024, then tumbled by 171.92% to 543000.0 in 2025, then plunged by 3656.91% to 20400000.0 in 2026.
- Business Quant data shows TNDM's Income from Continuing Operations at 20400000.0 in Q1 2026, 543000.0 in Q4 2025, and 21165000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | -20.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.40 Mn |
| Dec 31, 2025 | -543,000.00 |
| Sep 30, 2025 | -21.17 Mn |
| Jun 30, 2025 | -52.42 Mn |
| Mar 31, 2025 | -130.60 Mn |
| Dec 31, 2024 | 755,000.00 |
| Sep 30, 2024 | -23.21 Mn |
| Jun 30, 2024 | -30.81 Mn |
| Mar 31, 2024 | -42.73 Mn |
| Dec 31, 2023 | -29.97 Mn |
| Sep 30, 2023 | -32.96 Mn |
| Jun 30, 2023 | -35.75 Mn |
| Mar 31, 2023 | -123.90 Mn |
| Dec 31, 2022 | -15.89 Mn |
| Sep 30, 2022 | -48.95 Mn |
| Jun 30, 2022 | -15.05 Mn |
| Mar 31, 2022 | -14.74 Mn |
| Dec 31, 2021 | 10.76 Mn |
| Sep 30, 2021 | 5.75 Mn |
| Jun 30, 2021 | 4.00 Mn |